Web Date: April 5, 2016
Gilead buys Nimbus’s NASH portfolio
In a bid to strengthen its liver disease drug pipeline, Gilead Sciences will pay $400 million up front for Nimbus Therapeutics’ small molecules for nonalcoholic steatohepatitis (NASH), a liver disease that can lead to cirrhosis.
Currently, no drugs exist to treat NASH, which begins with fat deposits in the liver and can cause scar tissue to accumulate. Up to 5% of Americans have NASH and another 10–20% have fat in their liver, according to the . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society